225Ac-PSMA-617 (PSMA-617 with α-emitting radionuclide 225Ac) and 177Lu-J591 (177Lu with monoclonal antibody J591) are also currently under investigation as potential radioligand therapies for prostate cancer. Here, FOLH1 is linked to prostate carcinoma.